Kusai M. Al-Muqbel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kusai M. Al-Muqbel has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Rami Jalal Yaghan
Department of Surgery, College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Bahrain
2 shared publications Abdullah Rashdan
Jordan University of Science and Technology
1 shared publicationAli Abdel Kareem
King Abdullah University Hospital
1 shared publicationAmr Tashtoush
King Abdullah University Hospital
1 shared publicationFadia Mayyas
Jordan University of Science and Technology
1 shared publication- Karem H. Alzoubi
University of Sharjah
1 shared publication
Latest Publications
- Open Access
- 1 November 2025
- Published by Modestum Ltd in Electronic Journal of General Medicine
- Vol. 22 (6) , em696
Anatomical variations of the azygos lobe from a developing country population: A computed tomography study
Background: The right lung’s upper lobe can have an uncommon anatomical variant known as an azygos lobe (AL). Its etiology is associated with a malfunction in the azygos vein (AV)’s migration during embryonic development. This study aimed to determine the prevalence of the AL and its types from a developing country’s population. Methods: A total of 3,600 chest computed tomography images for patients who were undergoing imaging in the diagnostic radiology department at a major medical center were examined to determine whether the left or right AL and axial plane fissure were present. Furthermore, the differences in the size of the ALs and the shape of the fissures were also evaluated according to the different types of ALs. Results: The results revealed that, of the 3,600 subjects, only 0.92% had an AL, whereas 99.08% did not. The most prevalent azygos types were azygos type A (0.39%), followed by azygos type B (0.28%) and azygos type C (0.25%). AL abnormality is also very uncommon in both genders, with a frequency of 0.92% in females and 0.91% in males. Conclusion: Variants of the AL are rare; however, properly identifying this structure may reduce many associated problems, such as bleeding risk and accidental AV injury. Our results show that the most prevalent azygos type variation is type A, and the prevalence of the AL is comparable to the prevalence rate reported in the literature.
- 1 November 2025
- Published by Modestum Ltd in Electronic Journal of General Medicine
- Vol. 22 (6) , em696
Open AccessAnatomical variations of the azygos lobe from a developing country population: A computed tomography study
Background: The right lung’s upper lobe can have an uncommon anatomical variant known as an azygos lobe (AL). Its etiology is associated with a malfunction in the azygos vein (AV)’s migration during embryonic development. This study aimed to determine the prevalence of the AL and its types from a developing country’s population. Methods: A total of 3,600 chest computed tomography images for patients who were undergoing imaging in the diagnostic radiology department at a major medical center were examined to determine whether the left or right AL and axial plane fissure were present. Furthermore, the differences in the size of the ALs and the shape of the fissures were also evaluated according to the different types of ALs. Results: The results revealed that, of the 3,600 subjects, only 0.92% had an AL, whereas 99.08% did not. The most prevalent azygos types were azygos type A (0.39%), followed by azygos type B (0.28%) and azygos type C (0.25%). AL abnormality is also very uncommon in both genders, with a frequency of 0.92% in females and 0.91% in males. Conclusion: Variants of the AL are rare; however, properly identifying this structure may reduce many associated problems, such as bleeding risk and accidental AV injury. Our results show that the most prevalent azygos type variation is type A, and the prevalence of the AL is comparable to the prevalence rate reported in the literature.
- Open Access
- 2 September 2022
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 22 (01) , 7-14
Utility of 99mTechnetium Pertechnetate Thyroid Scan and Uptake in Thyrotoxic Patients: Jordanian Experience
Objective The objective of this study was to assess our local experience with 99mTechnitium thyroid uptake (TcTU) in thyrotoxicosis by examining mean and range of TcTU in both euthyroid patients and thyrotoxic patients. We also wanted to see how well TcTU performed as a substitute for radioiodine thyroid uptake in thyrotoxicosis. Methods The medical records of thyrotoxic patients were reviewed retrospectively. Inclusion criteria were: (1) thyrotoxicosis was proven biochemically, (2) the patient underwent TcTU at the time of thyrotoxicosis diagnosis, (3) at least 6 months of follow-up, and (4) the final diagnosis was documented. All TcTU of euthyroid patients were also reviewed to determine local normal TcTU mean and range. Patients were divided into three groups: Graves' disease, toxic nodular goiter, and subacute thyroiditis. Each patient group's TcTU mean and range were assessed separately. Results There were 209 patients in total (54 euthyroid, 112 Graves' disease, 26 toxic nodules, and 17 patients with subacute thyroiditis). TcTU mean±standard deviation and range for euthyroid patients were 1.5±1.1% and 0.17 to 4.8%, 10.6±10% and 0.43 to 40% for Graves' disease, 4.5±4% and 0.6 to 15% for toxic nodules, and 0.5±0.4% and 0.18 to 1% for subacute thyroiditis. Although one-third of thyrotoxic patients' TcTU values overlapped with the normal TcTU range, the diagnosis was made using qualitative image analysis. Subacute thyroiditis was characterized by poor thyroid visualization, whereas Graves'/toxic nodular goiter was well visualized. Conclusion The mean and range of our local normal TcTU were similar to those previously published. TcTU was a useful alternative to radioiodine in the evaluation of thyrotoxicosis. About two-thirds of the patients had accurate test results. The diagnosis was reached in the remaining one-third of patients by combining quantitative and qualitative image features. This method allowed us to stop giving radioiodine to our patients, resulting in a significant reduction in patient radiation exposure. Article published online: 02 September 2022 © 2022. World Association of Radiopharmaceutical and Molecular Therapy (WARMTH). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- 2 September 2022
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 22 (01) , 7-14
Open AccessUtility of 99mTechnetium Pertechnetate Thyroid Scan and Uptake in Thyrotoxic Patients: Jordanian Experience
Objective The objective of this study was to assess our local experience with 99mTechnitium thyroid uptake (TcTU) in thyrotoxicosis by examining mean and range of TcTU in both euthyroid patients and thyrotoxic patients. We also wanted to see how well TcTU performed as a substitute for radioiodine thyroid uptake in thyrotoxicosis. Methods The medical records of thyrotoxic patients were reviewed retrospectively. Inclusion criteria were: (1) thyrotoxicosis was proven biochemically, (2) the patient underwent TcTU at the time of thyrotoxicosis diagnosis, (3) at least 6 months of follow-up, and (4) the final diagnosis was documented. All TcTU of euthyroid patients were also reviewed to determine local normal TcTU mean and range. Patients were divided into three groups: Graves' disease, toxic nodular goiter, and subacute thyroiditis. Each patient group's TcTU mean and range were assessed separately. Results There were 209 patients in total (54 euthyroid, 112 Graves' disease, 26 toxic nodules, and 17 patients with subacute thyroiditis). TcTU mean±standard deviation and range for euthyroid patients were 1.5±1.1% and 0.17 to 4.8%, 10.6±10% and 0.43 to 40% for Graves' disease, 4.5±4% and 0.6 to 15% for toxic nodules, and 0.5±0.4% and 0.18 to 1% for subacute thyroiditis. Although one-third of thyrotoxic patients' TcTU values overlapped with the normal TcTU range, the diagnosis was made using qualitative image analysis. Subacute thyroiditis was characterized by poor thyroid visualization, whereas Graves'/toxic nodular goiter was well visualized. Conclusion The mean and range of our local normal TcTU were similar to those previously published. TcTU was a useful alternative to radioiodine in the evaluation of thyrotoxicosis. About two-thirds of the patients had accurate test results. The diagnosis was reached in the remaining one-third of patients by combining quantitative and qualitative image features. This method allowed us to stop giving radioiodine to our patients, resulting in a significant reduction in patient radiation exposure. Article published online: 02 September 2022 © 2022. World Association of Radiopharmaceutical and Molecular Therapy (WARMTH). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- Open Access
- 22 June 2020
- Published by Springer Nature in Research Square
Is 99mTechnetium Pertechnetate Thyroid Uptake accurate in Thyrotoxicosis Evaluation?
BackgroundThis study aimed to evaluate the 99mTc thyroid uptake (TcTU) in terms of (1) normal mean and range, (2) level of uncertainty in thyrotoxic patients and (3) effectiveness of adding radioiodine uptake in patients with uncertain TcTU values.MethodsPatients referred for TcTU test were included and categorized into groups: euthyroid, Graves’ disease, toxic nodular goiter and subacute thyroiditis. Mean and range of TcTU were obtained separately for each group. Second radioiodine uptake test was performed in patients who had uncertain TcTU (overlap with normal range). Results209 patients were included (54 euthyroid, 112 Graves’ disease, 29 toxic nodules and 17 subacute thyroiditis patients). Normal mean and range of TcTU were 1.5 +/- 1.1% and 0.17-4.8%, respectively. Mean TcTU was high in hyperthyroid patients and was extremely low in subacute thyroiditis patients, however, uncertain values was noted in about 30% of the patients. TcTU was uncertain in 39 hyperthyroid patients and in 10 subacute thyroiditis patients, while second radioiodine uptake was high in the former and extremely low in the latter.Test sensitivity was 68%, specificity was 100%, positive predictive value (PPV) was 100%, negative predictive value (NPV) was 52% and accuracy was 76%. ConclusionTcTU major disadvantage is the uncertainty seen in third of patients degrading test sensitivity and accuracy. We managed to overcome this uncertainty by adding second radioiodine thyroid uptake test. Accordingly, single visit TcTU was accurate and sufficient in about two thirds of patients while the remainder required second radioiodine uptake to reach accurate diagnosis.
- 22 June 2020
- Published by Springer Nature in Research Square
Open AccessIs 99mTechnetium Pertechnetate Thyroid Uptake accurate in Thyrotoxicosis Evaluation?
BackgroundThis study aimed to evaluate the 99mTc thyroid uptake (TcTU) in terms of (1) normal mean and range, (2) level of uncertainty in thyrotoxic patients and (3) effectiveness of adding radioiodine uptake in patients with uncertain TcTU values.MethodsPatients referred for TcTU test were included and categorized into groups: euthyroid, Graves’ disease, toxic nodular goiter and subacute thyroiditis. Mean and range of TcTU were obtained separately for each group. Second radioiodine uptake test was performed in patients who had uncertain TcTU (overlap with normal range). Results209 patients were included (54 euthyroid, 112 Graves’ disease, 29 toxic nodules and 17 subacute thyroiditis patients). Normal mean and range of TcTU were 1.5 +/- 1.1% and 0.17-4.8%, respectively. Mean TcTU was high in hyperthyroid patients and was extremely low in subacute thyroiditis patients, however, uncertain values was noted in about 30% of the patients. TcTU was uncertain in 39 hyperthyroid patients and in 10 subacute thyroiditis patients, while second radioiodine uptake was high in the former and extremely low in the latter.Test sensitivity was 68%, specificity was 100%, positive predictive value (PPV) was 100%, negative predictive value (NPV) was 52% and accuracy was 76%. ConclusionTcTU major disadvantage is the uncertainty seen in third of patients degrading test sensitivity and accuracy. We managed to overcome this uncertainty by adding second radioiodine thyroid uptake test. Accordingly, single visit TcTU was accurate and sufficient in about two thirds of patients while the remainder required second radioiodine uptake to reach accurate diagnosis.
- Open Access
- 13 August 2017
- Published by Wiley in BioMed Research International
- Vol. 2017, 1-7
Bone Marrow Metastasis Is an Early Stage of Bone Metastasis in Breast Cancer Detected Clinically by F18-FDG-PET/CT Imaging
Objective. To determine the value of 18F-FDG PET/CT in detection of bone marrow (BM) metastasis in breast cancer which is considered an early stage of bone metastasis. Patients and Methods. Retrospectively, breast cancer patients with bone metastasis were included. BM metastasis was considered if the lesion was PET positive/CT occult while bone metastasis was considered if the lesion was PET positive/ CT positive. BM metastases were observed sequentially on F18-FDG PET/CT. Results. We included 35 patients. Eighteen patients (51%) had BM metastases in addition to other bone metastases. BM metastases comprised 24% of all lesions. Posttreatment scan was performed on 26/35 patients. Twenty-three percent of BM metastases had resolved completely without causing bone destruction after treatment. Sixty-five percent of BM metastases had converted into bone metastases after treatment. Twelve percent of BM metastases had persisted after treatment. Conclusion. This retrospective study showed clinically by 18F-FDG PET/CT imaging that BM metastasis is an early stage of bone metastasis in breast cancer. Interestingly, 18F-FDG-PET/CT showed that early eradication of individual BM metastasis by systemic treatment precluded development of bone metastasis. However, more research is needed to study the impact of an early diagnosis of BM metastases on treatment outcome.
- 13 August 2017
- Published by Wiley in BioMed Research International
- Vol. 2017, 1-7
Open AccessBone Marrow Metastasis Is an Early Stage of Bone Metastasis in Breast Cancer Detected Clinically by F18-FDG-PET/CT Imaging
Objective. To determine the value of 18F-FDG PET/CT in detection of bone marrow (BM) metastasis in breast cancer which is considered an early stage of bone metastasis. Patients and Methods. Retrospectively, breast cancer patients with bone metastasis were included. BM metastasis was considered if the lesion was PET positive/CT occult while bone metastasis was considered if the lesion was PET positive/ CT positive. BM metastases were observed sequentially on F18-FDG PET/CT. Results. We included 35 patients. Eighteen patients (51%) had BM metastases in addition to other bone metastases. BM metastases comprised 24% of all lesions. Posttreatment scan was performed on 26/35 patients. Twenty-three percent of BM metastases had resolved completely without causing bone destruction after treatment. Sixty-five percent of BM metastases had converted into bone metastases after treatment. Twelve percent of BM metastases had persisted after treatment. Conclusion. This retrospective study showed clinically by 18F-FDG PET/CT imaging that BM metastasis is an early stage of bone metastasis in breast cancer. Interestingly, 18F-FDG-PET/CT showed that early eradication of individual BM metastasis by systemic treatment precluded development of bone metastasis. However, more research is needed to study the impact of an early diagnosis of BM metastases on treatment outcome.
- Open Access
- 1 May 2016
- Published by Wolters Kluwer Health in Medicine
- Vol. 95 (21) , e3753
Effectiveness of 18F-FDG-PET/CT vs Bone Scintigraphy in Treatment Response Assessment of Bone Metastases in Breast Cancer
The aim of the study was to examine the effectiveness of fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) versus bone scintigraphy (BS) in treatment response assessment of bone metastases in breast cancer.The medical records of breast cancer patients with metastatic bone disease were reviewed retrospectively in our hospital from the period of January 2003 until April 2014. We included in our study patients evaluated by BS and/or 18F-FDG-PET/CT. Group 1 included patients who underwent pre- and post-treatment BS. Group 2 included patients who underwent pre- and post-treatment 18F-FDG-PET/CT scans. Group 3 included patients who underwent pretreatment BS and post-treatment both modalities. Functional and structural bone changes were monitored on pre- and post-treatment scans.Group 1 included 71 patients, average age of 49.5 y (range 28-73 y). Post-treatment results were as follows: 34% stable disease, 43% progressed disease, 19% improved disease, 3% resolved disease, and 2% relapsed disease. Group 2 included 32 patients, average age 53.2 y (ranges between 37 and 78 y). Post-treatment results were as follows: 3% stable disease, 15% progressed disease, 15% improved disease, 53% resolved disease, and 14% relapsed disease. After treatment, the total symptomatic/imaging concordance rate was 51% in BS and 83% in 18F-FDG-PET/CT. Structurally, most patients with newly diagnosed metastatic bone disease had predominantly osteolytic lesions, which became mixed or osteoblastic after treatment as noted on CT images of responders. Group 3 included 8 patients, average age 48.9 y (ranges 32-64 y). Five patients had stable disease according to BS. 18F-FDG-PET/CT was concordant in 3/5 patients and discordant in 2/5 patients. Three patients had progressed disease on BS with concordant findings on 18F-FDG-PET/CT.18F-FDG-PET/CT was found a powerful tool in treatment response assessment of bone metastases in breast cancer and consistent with clinical status of the patients as it reflects tumor activity. BS is insufficient for response assessment of bone metastases as it reflects osteoblastic reaction of the bone against metastatic disease which increases as the disease responds to treatment.
- 1 May 2016
- Published by Wolters Kluwer Health in Medicine
- Vol. 95 (21) , e3753
Open AccessEffectiveness of 18F-FDG-PET/CT vs Bone Scintigraphy in Treatment Response Assessment of Bone Metastases in Breast Cancer
The aim of the study was to examine the effectiveness of fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) versus bone scintigraphy (BS) in treatment response assessment of bone metastases in breast cancer.The medical records of breast cancer patients with metastatic bone disease were reviewed retrospectively in our hospital from the period of January 2003 until April 2014. We included in our study patients evaluated by BS and/or 18F-FDG-PET/CT. Group 1 included patients who underwent pre- and post-treatment BS. Group 2 included patients who underwent pre- and post-treatment 18F-FDG-PET/CT scans. Group 3 included patients who underwent pretreatment BS and post-treatment both modalities. Functional and structural bone changes were monitored on pre- and post-treatment scans.Group 1 included 71 patients, average age of 49.5 y (range 28-73 y). Post-treatment results were as follows: 34% stable disease, 43% progressed disease, 19% improved disease, 3% resolved disease, and 2% relapsed disease. Group 2 included 32 patients, average age 53.2 y (ranges between 37 and 78 y). Post-treatment results were as follows: 3% stable disease, 15% progressed disease, 15% improved disease, 53% resolved disease, and 14% relapsed disease. After treatment, the total symptomatic/imaging concordance rate was 51% in BS and 83% in 18F-FDG-PET/CT. Structurally, most patients with newly diagnosed metastatic bone disease had predominantly osteolytic lesions, which became mixed or osteoblastic after treatment as noted on CT images of responders. Group 3 included 8 patients, average age 48.9 y (ranges 32-64 y). Five patients had stable disease according to BS. 18F-FDG-PET/CT was concordant in 3/5 patients and discordant in 2/5 patients. Three patients had progressed disease on BS with concordant findings on 18F-FDG-PET/CT.18F-FDG-PET/CT was found a powerful tool in treatment response assessment of bone metastases in breast cancer and consistent with clinical status of the patients as it reflects tumor activity. BS is insufficient for response assessment of bone metastases as it reflects osteoblastic reaction of the bone against metastatic disease which increases as the disease responds to treatment.
- 21 October 2013
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine Technology
- Vol. 41 (4) , 308-310
Osteoblastoma Is a Metabolically Active Benign Bone Tumor on 18F-FDG PET Imaging
We describe a case of a 9-y-old girl who on 18F-FDG PET imaging was found to have a highly metabolically active sacral tumor with an average standarized uptake value of 6.2. The tumor was proven to be osteoblastoma by pathologic examination. Osteoblastoma is a relatively rare benign primary bone tumor and occurs predominantly in patients younger than 20 y. The most common area of involvement is the spine. Osteoblastoma has been reported to be metabolically active on 18F-FDG PET imaging, with an average standarized uptake value of 3.2, which renders 18F-FDG PET imaging unable to differentiate benign from malignant primary bone tumors. To our knowledge, only 5 cases of osteoblastoma evaluated by 18F-FDG PET imaging have been reported in the literature; all were metabolically active on 18F-FDG PET imaging. The objective of this case report is to show that a metabolically active primary bone tumor on 18F-FDG PET imaging might be benign and not necessarily malignant.
- 21 October 2013
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine Technology
- Vol. 41 (4) , 308-310
Osteoblastoma Is a Metabolically Active Benign Bone Tumor on 18F-FDG PET Imaging
We describe a case of a 9-y-old girl who on 18F-FDG PET imaging was found to have a highly metabolically active sacral tumor with an average standarized uptake value of 6.2. The tumor was proven to be osteoblastoma by pathologic examination. Osteoblastoma is a relatively rare benign primary bone tumor and occurs predominantly in patients younger than 20 y. The most common area of involvement is the spine. Osteoblastoma has been reported to be metabolically active on 18F-FDG PET imaging, with an average standarized uptake value of 3.2, which renders 18F-FDG PET imaging unable to differentiate benign from malignant primary bone tumors. To our knowledge, only 5 cases of osteoblastoma evaluated by 18F-FDG PET imaging have been reported in the literature; all were metabolically active on 18F-FDG PET imaging. The objective of this case report is to show that a metabolically active primary bone tumor on 18F-FDG PET imaging might be benign and not necessarily malignant.
- 1 June 2013
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 34 (6) , 577-581
Value of baseline and follow-up whole-body bone scans in detecting bone metastasis in high-risk breast cancer patients
Objective The aim of the study was to test the value of routine baseline and follow-up bone scans in societies with a prevalence of high-risk breast cancer features. Patients and methods The medical records of 261 Jordanian breast cancer patients were reviewed. Patients who had (a) breast cancer proven by pathology, (b) had undergone a baseline bone scan, and (c) had undergone follow-up bone scan(s) for at least 12 months were included in the study. The patients were divided into three groups. Group 1 included 171 patients who had negative bone scans; group 2 included 52 patients who had negative baseline bone scans but developed bone metastasis on follow-up; and group 3 included 38 patients who had bone metastasis at presentation. Results Patients’ ages ranged between 21 and 85 years with mean±SD of 49.7 (±11.3) years. About 55% of our patients were younger than 50 years. Clinicopathological stages were as follows: 14% of patients were in stage I, 42% were in stage II, 30% were in stage III, and 14% were in stage IV. A significant proportion of our patients have high-risk features. Fourteen percent of the patients already had bone metastasis at diagnosis and 20% developed bone metastasis on follow-up. Sixty percent of group 2 patients developed bone metastasis within 2 years after diagnosis and the rest (40%) developed bone metastasis 2 years after diagnosis (≤13 years). Conclusion Within the limitations of this retrospective study, in a country like Jordan with greater prevalence of high-risk breast cancer features, a routine baseline whole-body bone scan might be justifiable. Follow-up whole-body bone scans might result in better quality of life and lower skeletal-related morbidity. Further prospective work is suggested.
- 1 June 2013
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 34 (6) , 577-581
Value of baseline and follow-up whole-body bone scans in detecting bone metastasis in high-risk breast cancer patients
Objective The aim of the study was to test the value of routine baseline and follow-up bone scans in societies with a prevalence of high-risk breast cancer features. Patients and methods The medical records of 261 Jordanian breast cancer patients were reviewed. Patients who had (a) breast cancer proven by pathology, (b) had undergone a baseline bone scan, and (c) had undergone follow-up bone scan(s) for at least 12 months were included in the study. The patients were divided into three groups. Group 1 included 171 patients who had negative bone scans; group 2 included 52 patients who had negative baseline bone scans but developed bone metastasis on follow-up; and group 3 included 38 patients who had bone metastasis at presentation. Results Patients’ ages ranged between 21 and 85 years with mean±SD of 49.7 (±11.3) years. About 55% of our patients were younger than 50 years. Clinicopathological stages were as follows: 14% of patients were in stage I, 42% were in stage II, 30% were in stage III, and 14% were in stage IV. A significant proportion of our patients have high-risk features. Fourteen percent of the patients already had bone metastasis at diagnosis and 20% developed bone metastasis on follow-up. Sixty percent of group 2 patients developed bone metastasis within 2 years after diagnosis and the rest (40%) developed bone metastasis 2 years after diagnosis (≤13 years). Conclusion Within the limitations of this retrospective study, in a country like Jordan with greater prevalence of high-risk breast cancer features, a routine baseline whole-body bone scan might be justifiable. Follow-up whole-body bone scans might result in better quality of life and lower skeletal-related morbidity. Further prospective work is suggested.
- Open Access
- 25 April 2012
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 56 (4) , 384-389
Radiofrequency ablation of osteoid osteoma using tissue impedance as a parameter of osteonecrosis
Introduction: The aim of this study is to assess the safety and the efficacy of radiofrequency ablation (RFA) of osteoid osteoma with Soloist monopolar electrode using tissue impedance, rather than temperature, as an indicator of osteonecrosis.Methods: The medical records and imaging studies of 30 patients (males 18, females 12) who underwent RFA of osteoid osteoma at our institution were reviewed. The mean age of the patients was 15.3 years (range 5–34 years) and the mean duration of follow up was 26.9 months (range 3–52 months). The lesions were located in the femur (n = 6, 53%), tibia (n = 8, 27%), hand (n = 3, 10%), foot (n = 2, 6%) and humerus (n = 1, 3%). The procedure was performed with general anaesthesia under CT guidance. The nidus was accessed with 11‐gauge bone biopsy needle and then the stylet was removed and replaced by monopolar 16.5G radiofrequency probe with a 9‐mm active tip through the coaxial axis. Power delivery via the radiofrequency generator was started at 2 W and increased gradually until the end point of 450–500 Ω reached and ‘Roll‐Off’ achieved indicating coagulation necrosis of the target lesion.Results: The procedure was technically successful in all patients. The mean procedure time was 72 min and the mean RFA time was 12.7 min. The clinical success rate was 93%. In one patient, the procedure was abandoned due to immature Roll‐Off despite all measures. In one patient (3%), recurrence occurred 39 months after the procedure. No major complications were encountered. Two minor skin burns occurred that were resolved with conservative measures.Conclusion: RFA of osteoid osteoma using Soloist monopolar electrode is a safe and effective treatment. Tissue impedance could be used as an alternative to temperature to indicate osteonecrosis of osteoid osteoma during RFA.
- 25 April 2012
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 56 (4) , 384-389
Open AccessRadiofrequency ablation of osteoid osteoma using tissue impedance as a parameter of osteonecrosis
Introduction: The aim of this study is to assess the safety and the efficacy of radiofrequency ablation (RFA) of osteoid osteoma with Soloist monopolar electrode using tissue impedance, rather than temperature, as an indicator of osteonecrosis.Methods: The medical records and imaging studies of 30 patients (males 18, females 12) who underwent RFA of osteoid osteoma at our institution were reviewed. The mean age of the patients was 15.3 years (range 5–34 years) and the mean duration of follow up was 26.9 months (range 3–52 months). The lesions were located in the femur (n = 6, 53%), tibia (n = 8, 27%), hand (n = 3, 10%), foot (n = 2, 6%) and humerus (n = 1, 3%). The procedure was performed with general anaesthesia under CT guidance. The nidus was accessed with 11‐gauge bone biopsy needle and then the stylet was removed and replaced by monopolar 16.5G radiofrequency probe with a 9‐mm active tip through the coaxial axis. Power delivery via the radiofrequency generator was started at 2 W and increased gradually until the end point of 450–500 Ω reached and ‘Roll‐Off’ achieved indicating coagulation necrosis of the target lesion.Results: The procedure was technically successful in all patients. The mean procedure time was 72 min and the mean RFA time was 12.7 min. The clinical success rate was 93%. In one patient, the procedure was abandoned due to immature Roll‐Off despite all measures. In one patient (3%), recurrence occurred 39 months after the procedure. No major complications were encountered. Two minor skin burns occurred that were resolved with conservative measures.Conclusion: RFA of osteoid osteoma using Soloist monopolar electrode is a safe and effective treatment. Tissue impedance could be used as an alternative to temperature to indicate osteonecrosis of osteoid osteoma during RFA.
- 13 October 2010
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 44 (4) , 246-251
Reproducibility of Gallbladder Ejection Fraction Measured by Fatty Meal Cholescintigraphy
There are conflicting data in the literature regarding the reproducibility of the gallbladder ejection fraction (GBEF) measured by fatty meal cholescintigraphy (CS). We aimed to test the reproducibility of GBEF measured by fatty meal CS. Thirty-five subjects (25 healthy volunteers and 10 patients with chronic abdominal pain) underwent fatty meal CS twice in order to measure GBEF1 and GBEF2. The healthy volunteers underwent a repeat scan within 1-13 months from the first scan. The patients underwent a repeat scan within 1-4 years from the first scan and were not found to have chronic acalculous cholecystitis (CAC). Our standard fatty meal was composed of a 60-g Snickers chocolate bar and 200 ml full-fat yogurt. The mean ± SD values for GBEF1 and GBEF2 were 52 ± 17% and 52 ± 16%, respectively. There was a direct linear correlation between the values of GBEF1 and GBEF2 for the subjects, with a correlation coefficient of 0.509 (p = 0.002). Subgroup data analysis of the volunteer group showed that there was significant linear correlation between volunteer values of GBEF1 and GBEF2, with a correlation coefficient of 0.473 (p = 0.017). Subgroup data analysis of the non-CAC patient group showed no significant correlation between patient values of GBEF1 and GBEF2, likely due to limited sample size. This study showed that fatty meal CS is a reliable test in gallbladder motility evaluation and that GBEF measured by fatty meal CS is reproducible.
- 13 October 2010
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 44 (4) , 246-251
Reproducibility of Gallbladder Ejection Fraction Measured by Fatty Meal Cholescintigraphy
There are conflicting data in the literature regarding the reproducibility of the gallbladder ejection fraction (GBEF) measured by fatty meal cholescintigraphy (CS). We aimed to test the reproducibility of GBEF measured by fatty meal CS. Thirty-five subjects (25 healthy volunteers and 10 patients with chronic abdominal pain) underwent fatty meal CS twice in order to measure GBEF1 and GBEF2. The healthy volunteers underwent a repeat scan within 1-13 months from the first scan. The patients underwent a repeat scan within 1-4 years from the first scan and were not found to have chronic acalculous cholecystitis (CAC). Our standard fatty meal was composed of a 60-g Snickers chocolate bar and 200 ml full-fat yogurt. The mean ± SD values for GBEF1 and GBEF2 were 52 ± 17% and 52 ± 16%, respectively. There was a direct linear correlation between the values of GBEF1 and GBEF2 for the subjects, with a correlation coefficient of 0.509 (p = 0.002). Subgroup data analysis of the volunteer group showed that there was significant linear correlation between volunteer values of GBEF1 and GBEF2, with a correlation coefficient of 0.473 (p = 0.017). Subgroup data analysis of the non-CAC patient group showed no significant correlation between patient values of GBEF1 and GBEF2, likely due to limited sample size. This study showed that fatty meal CS is a reliable test in gallbladder motility evaluation and that GBEF measured by fatty meal CS is reproducible.
- 25 November 2009
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 24 (1) , 29-34
Gallbladder ejection fraction measured by fatty meal cholescintigraphy: is it affected by extended gallbladder emptying data acquisition time?
The main objective of this study was to determine the effect of gallbladder emptying acquisition time on gallbladder ejection fraction (GBEF) measurement obtained by fatty meal cholescintigraphy (CS). During fatty meal cholescintigraphy (CS), GBEF1 and GBEF2 were calculated 20 and 45 min, respectively, post meal ingestion on 50 healthy volunteers, 37 patients with chronic acalculous cholecystitis (CAC) and 20 non-CAC patients. GBEF1/GBEF2 was calculated and represented the percentage of GBEF occurred during 20 min after meal ingestion. The gallbladder was classified as ended pattern if it terminated contraction before the end of data acquisition or classified as continuous pattern if it continued to contract before the end of data acquisition. Mean GBEF in continuous pattern was compared with mean GBEF in ended pattern in each group. Gallbladder emptying had two phases; early rapid phase and late slow phase. About two-thirds of ejected volume occurred within the rapid phase. About half of gallbladders in each group were classified as ended pattern while the other half was classified as continuous pattern. There was no significant difference in mean GBEF values between both patterns in each group. GBEF measurement obtained by CS is not affected by further extension of gallbladder emptying data acquisition beyond the standard 45–60 min acquisition time.
- 25 November 2009
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 24 (1) , 29-34
Gallbladder ejection fraction measured by fatty meal cholescintigraphy: is it affected by extended gallbladder emptying data acquisition time?
The main objective of this study was to determine the effect of gallbladder emptying acquisition time on gallbladder ejection fraction (GBEF) measurement obtained by fatty meal cholescintigraphy (CS). During fatty meal cholescintigraphy (CS), GBEF1 and GBEF2 were calculated 20 and 45 min, respectively, post meal ingestion on 50 healthy volunteers, 37 patients with chronic acalculous cholecystitis (CAC) and 20 non-CAC patients. GBEF1/GBEF2 was calculated and represented the percentage of GBEF occurred during 20 min after meal ingestion. The gallbladder was classified as ended pattern if it terminated contraction before the end of data acquisition or classified as continuous pattern if it continued to contract before the end of data acquisition. Mean GBEF in continuous pattern was compared with mean GBEF in ended pattern in each group. Gallbladder emptying had two phases; early rapid phase and late slow phase. About two-thirds of ejected volume occurred within the rapid phase. About half of gallbladders in each group were classified as ended pattern while the other half was classified as continuous pattern. There was no significant difference in mean GBEF values between both patterns in each group. GBEF measurement obtained by CS is not affected by further extension of gallbladder emptying data acquisition beyond the standard 45–60 min acquisition time.